• Hong Kong grants Patent Family 4 for RECCE® 327 (R327) and RECCE® 529 (R529) anti-infectives
• Patent covers process, use, and administration of RECCE anti-infectives for treating bacterial, viral, and other infections
• This is the 6th patent granted for RECCE anti-infectives, strengthening the company's intellectual property portfolio in Asia

Recce Pharmaceuticals Ltd has announced that the Hong Kong Special Administrative Region has formally granted Patent Family 4 for its RECCE® Anti-Infectives, with an expiry date of 2041. The Hong Kong Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), covering the process for preparation, use for the treatment of disease (particularly bacterial and viral infections), and administration methods (oral, inhalation, transdermal, injection). This is the company's sixth Family 4 patent, alongside existing patents in Australia, Canada, Israel, Japan, and China, with further Patent Cooperation Treaty (PCT) submissions in respective stages of review or allowance. The Hong Kong pharmaceutical market is valued at around US$2.5 billion and projected to grow at a 6.5% CAGR from 2025 to 2030. Recce continues to progress its Phase 3 clinical trial in Indonesia and is seeking further approval pathways across ASEAN markets. The strengthening of its intellectual property portfolio in nations such as Hong Kong further supports the company's regional strategy, enabling market entry opportunities in territories where demand for next-generation anti-infectives continues to grow.

Recce Pharmaceuticals is continuing to progress its Phase 3 clinical trial in Indonesia and is seeking further approval pathways across ASEAN markets. The strengthening of its intellectual property portfolio in nations such as Hong Kong further supports the company's regional strategy, enabling market entry opportunities in territories where demand for next-generation anti-infectives continues to grow.